Stability
Storage
Oral
Tablets
2–30°C.
Intranasal
Solution
2–30°C; protect from light.
Parenteral
Injection
2–30°C; protect from light.
Actions
- Binds with high affinity to 5-HT type 1-like receptors, probably 5-HT1B and 5-HT1D subtypes.
- Precise mechanism of action not established; may ameliorate migraine and cluster headache through selective constriction of certain large cranial blood vessels and/or inhibition of neurogenic inflammatory processes in the CNS.
Advice to Patients
- Importance of immediately informing a clinician of any tightness, pain, pressure, or heaviness in chest, throat, jaw, or neck, as well as sudden and/or severe abdominal pain, shortness of breath, wheezing, heart throbbing, facial swelling (e.g., eyelids, face, lips), rash, or hives after taking sumatriptan and of not taking sumatriptan again until evaluated by a clinician.
- Importance of taking sumatriptan exactly as prescribed.
- Importance of providing patient a copy of manufacturer’s patient information. Importance of clinician providing adequate instructions, as well as the written administration instructions supplied with the autoinjection device or nasal spray, before first use.
- Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses (e.g., cardiovascular disease).
- Importance of informing patients of risk of serotonin syndrome with concurrent use of sumatriptan and an SSRI or SNRI. Importance of seeking immediate medical attention if symptoms of serotonin syndrome develop.
- Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
- Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Sumatriptan
| Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|
| Nasal | Solution | 5 mg/0.1 mL |
Imitrex® Nasal Spray | GlaxoSmithKline |
| | 20 mg/0.1 mL |
Imitrex® Nasal Spray | GlaxoSmithKline |
Sumatriptan Succinate
| Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|
| Oral | Tablets, film-coated | 25 mg (of sumatriptan) |
Imitrex® | GlaxoSmithKline |
| | 50 mg (of sumatriptan) |
Imitrex® | GlaxoSmithKline |
| | 100 mg (of sumatriptan) |
Imitrex® | GlaxoSmithKline |
| Parenteral | Injection, for sub-Q use only | 4 mg/0.5 mL (of sumatriptan) |
Imitrex® (available in 0.5-mL [4-mg] unit-of-use syringes) | GlaxoSmithKline |
| | 6 mg/0.5 mL (of sumatriptan) |
Imitrex® (available in 0.5-mL [6-mg] unit-of-use syringes and as 0.5 mL [6-mg] single-dose vials) | GlaxoSmithKline |
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
| Imitrex 100MG Tablets | GLAXO SMITH KLINE | 9/$199.25 or 27/$575.5 |
| Imitrex 20MG/ACT Solution | GLAXO SMITH KLINE | 6/$209.99 or 18/$594.95 |
| Imitrex 25MG Tablets | GLAXO SMITH KLINE | 9/$214.01 or 27/$617.78 |
| Imitrex 5MG/ACT Solution | GLAXO SMITH KLINE | 1/$42.99 or 3/$112.97 |
| Imitrex 50MG Tablets | GLAXO SMITH KLINE | 9/$199.25 or 27/$575.5 |
| Imitrex 6MG/0.5ML Solution | GLAXO SMITH KLINE | 2/$397.13 or 7/$1151.7 |
AHFS Drug Information. © Copyright, 1959-2008, Selected Revisions August 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
Remember, keep this and all other medicines out of the reach of children,
never share your medicines with others, and use this medication only for the indication prescribed.
Print
Email
Drug Info Tools
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
